Contra-indicated in patients with hypokalemia, hypomagnesemia, or long QT syndrome.
- TRADE NAME: Tasigna (Novartis)
- INDICATIONS: Chronic myelogenous leukemia
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Bcr-Abl tyrosine kinase inhibitor / (Breakpoint cluster region Abelson (Bcr-Abl) tyrosine kinase inhibitor, Tyrosine kinase inhibitor, Vascular endothelial growth factor (VEGF) inhibitor / antagonist
- HALF-LIFE: 17 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, Amitriptyline, Amoxapine, Arsenic, Astemizole, Bepridil, Carbamazepine, Chloroquine, Cisapride, Citalopram, Clarithromycin, Clozapine, Conivaptan, Darunavir, Dasatinib, Degarelix, Delavirdine, Digoxin, Dihydroergotamine, Disopyramide, Dolasetron, Efavirenz, Ergotamine, Grapefruit Juice, Halofantrine, Haloperidol, Indinavir, Itraconazole, Ketoconazole, Lapatinib, Levofloxacin, Lopinavir, Methadone, Midazolam, Moxifloxacin, Oxcarbazepine, Pazopanib, Phenobarbital, Phenytoin, Pimozide, Procainamide, Quinidine, Rifampin, Rifapentine, Ritonavir, Sotalol, St John's Wort, Telavancin, Telithromycin, Terfenadine, Voriconazole, Vorinostat, Ziprasidone
- See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
Vascular endothelial growth factor (VEGF) inhibitor / antagonist
QT PROLONGATION AND SUDDEN DEATHS
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of nilotinib in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 06/26/2025
